| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/22/2001 | CA2384855A1 Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
| 03/22/2001 | CA2384783A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | CA2384782A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | CA2384726A1 Formulations for parenteral use of estramustine phosphate and amino acids |
| 03/22/2001 | CA2384646A1 Taxane prodrugs |
| 03/22/2001 | CA2384445A1 Methods and compositions for the screening of cell cycle modulators |
| 03/22/2001 | CA2384324A1 Proteins associated with cell differentiation |
| 03/22/2001 | CA2384294A1 Nicotinic acetylcholine receptor: alpha10 subunit |
| 03/22/2001 | CA2384246A1 Glucosamine and egg reducing inflammation |
| 03/22/2001 | CA2383927A1 Protein phosphatase and kinase proteins |
| 03/22/2001 | CA2383402A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 03/22/2001 | CA2383177A1 Human g-protein coupled receptor |
| 03/22/2001 | CA2383026A1 Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| 03/22/2001 | CA2382908A1 Composition for ivf |
| 03/22/2001 | CA2382633A1 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | CA2381078A1 Method of potentiating chemotherapy and treating solid tumors |
| 03/22/2001 | CA2381066A1 Polymorphisms in the human hpxr gene and their use in diagnostic and therapeutic applications |
| 03/22/2001 | CA2379541A1 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 03/21/2001 | EP1085323A2 NADE binding proteins |
| 03/21/2001 | EP1085092A1 Phosphodiesterase enzymes |
| 03/21/2001 | EP1085089A2 Human cyclic nucleotide phosphodiesterase |
| 03/21/2001 | EP1084711A1 Remedies for itching containing pgd 2? antagonists |
| 03/21/2001 | EP1084705A2 Method for lowering blood glucose levels in mammals |
| 03/21/2001 | EP1084569A2 Pharmaceutical combinations for compensating for a testosterone deficiency in men while simultaneously protecting the prostate |
| 03/21/2001 | EP1084255A1 Tankyrase, a trf1 binding protein |
| 03/21/2001 | EP1084241A1 G-protein coupled receptor, named 2871 receptor |
| 03/21/2001 | EP1084135A1 The human kidney specific gene kk86 |
| 03/21/2001 | EP1084114A1 Isothiazole derivatives useful as anticancer agents |
| 03/21/2001 | EP1083980A2 Modulation of molecular interaction sites on rna and other biomolecules |
| 03/21/2001 | EP1083932A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine |
| 03/21/2001 | EP1083931A1 Stabilization of compositions containing ace inhibitors using magnesium oxide |
| 03/21/2001 | EP1083929A2 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 03/21/2001 | EP1083927A1 HUMAN MINOR VAULT PROTEIN p193 |
| 03/21/2001 | EP1083924A1 Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 03/21/2001 | EP1083923A1 Acrp30r1: a homolog of acrp30 (30 kd adipocyte complement-related protein) |
| 03/21/2001 | EP1083921A1 Novel leukotriene receptor antagonists and their uses |
| 03/21/2001 | EP1083917A1 Novel analgesic agents |
| 03/21/2001 | EP1083916A1 IL-6/sIL-6R COMPLEX FOR PROMOTION OF LIVER FUNCTIONS |
| 03/21/2001 | EP1083914A1 Treatment of arthritis and other similar conditions |
| 03/21/2001 | EP1083910A1 nrdE |
| 03/21/2001 | EP1083909A1 hCEPR RECEPTOR |
| 03/21/2001 | EP1083906A1 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue |
| 03/21/2001 | EP1083905A2 Selective estrogen receptor modulator in combination with dehydroepiandrosterone (dhea) or analogues |
| 03/21/2001 | EP1083897A1 Hiv integrase inhibitors |
| 03/21/2001 | EP1083896A1 Use of neomycin for treating angiogenesis-related diseases |
| 03/21/2001 | EP1083893A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the d 1? receptors |
| 03/21/2001 | EP1083892A1 Topical application of muscarinic analgesic drugs such as neostigmine |
| 03/21/2001 | EP1083889A2 Method for treating neurodegenerative disorders |
| 03/21/2001 | EP1083888A1 MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS |
| 03/21/2001 | EP1083887A2 Pharmaceutical compositions for ulcer |
| 03/21/2001 | EP1083886A1 Drug delivery system comprising a tightly compacted solid medicament stock |
| 03/21/2001 | CN1288007A 6-carbonyl-3-(4-[2-(pierid-1-yl)elhoyl]phenoxy)-2(4-methoxylphenyl) benzo[b]thiophene salt crystal |
| 03/20/2001 | US6204388 Using blocking agent |
| 03/20/2001 | US6204258 Enhancing hair growth or treating alopecia in a subject uses topically administered estrogen receptor antagonists. |
| 03/20/2001 | US6204248 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 03/20/2001 | US6204245 Treatment of narcolepsy with immunosuppressants |
| 03/20/2001 | US6204244 Amino acid compositions and use thereof in immunosuppression |
| 03/20/2001 | US6204042 Isolated polynucleotide segment |
| 03/20/2001 | US6204019 Sec A2 from Streptococcus pneumoniae |
| 03/20/2001 | US6204015 Aminopeptidase from staphylococcus aureus |
| 03/20/2001 | US6204001 Methods for determining compounds capable of inhibiting the activities of the Ha-Ras oncongene |
| 03/20/2001 | US6203813 Opiate antagonist, steroidal antiinflammatory agent and carrier; sustained release; drug abuse treatment |
| 03/20/2001 | US6203800 Screening for antibacterial agents; genetic engineering |
| 03/20/2001 | US6203792 Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof |
| 03/20/2001 | US6203782 Topically applying anole, anethole or polymers thereof and/or fenchone; remelanization |
| 03/20/2001 | CA2237979C Reduction of hair growth |
| 03/20/2001 | CA2102429C Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| 03/15/2001 | WO2001018546A2 Screening for inhibitors of 'paired helical filaments' |
| 03/15/2001 | WO2001018236A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 03/15/2001 | WO2001018234A1 Method to identify gene function using small molecule probes |
| 03/15/2001 | WO2001018204A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 03/15/2001 | WO2001018176A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | WO2001018172A2 Fibroblast growth factor-like polypeptides |
| 03/15/2001 | WO2001018161A2 Process for the preparation of conjugated linoleic acid (cla) |
| 03/15/2001 | WO2001018051A2 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| 03/15/2001 | WO2001018047A1 Dendritic cell membrane protein fire |
| 03/15/2001 | WO2001018042A2 Apoptosis proteins |
| 03/15/2001 | WO2001018040A2 Use of leptin in inhibition of endothelial cell proliferation |
| 03/15/2001 | WO2001018006A1 Inhibitors of prenyl-protein transferase |
| 03/15/2001 | WO2001017995A1 Tyrosine kinase inhibitors |
| 03/15/2001 | WO2001017994A1 Oxazole ppar antagonists |
| 03/15/2001 | WO2001017985A1 Novel derivatives of flavones, xanthones and coumarins |
| 03/15/2001 | WO2001017959A2 Vitronectin receptor antagonists |
| 03/15/2001 | WO2001017954A1 Bile acid-substituted phenyl-alkenoylguanidines, method for producing said phenyl-alkenoylguanidines, use thereof as medicaments or diagnostic reagents and medicaments containing the same |
| 03/15/2001 | WO2001017596A1 Method of treating cardio pulmonary diseases with no group compounds |
| 03/15/2001 | WO2001017558A2 Novel uses of mammalian ccr6 receptors and related reagents |
| 03/15/2001 | WO2001017550A2 Vaccine against hbv and hpv |
| 03/15/2001 | WO2001017543A2 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 03/15/2001 | WO2001017527A1 Preventive and therapeutic agents for eye diseases |
| 03/15/2001 | WO2001017525A1 Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| 03/15/2001 | WO2001017524A1 Methods for treating cell proliferative disorders including cancer |
| 03/15/2001 | WO2001017523A1 Compositions and methods for modification of skin lipid content |
| 03/15/2001 | WO2001017522A1 Method of treating cancer using tetraethyl thiuram disulfide |
| 03/15/2001 | WO2001017521A1 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 03/15/2001 | WO2001017516A2 Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
| 03/15/2001 | WO2001017514A1 Modulation of gene expression by modulating histone acetylation |
| 03/15/2001 | WO2001017513A2 Pharmaceutical composition comprising an insulin sensitizer |
| 03/15/2001 | WO2001017506A1 Proteinic drug delivery system using membrane mimetics |
| 03/15/2001 | WO2001017498A1 Use of conjugated linoleic acid (cla) for the topical treatment of cellulite |
| 03/15/2001 | WO2001017497A1 Depigmenting compositions |